ArticleOxidative medicine and cellular longevity2022
Ligustilide Improves Cognitive Impairment via Regulating the SIRT1/IRE1
Article in Oxidative medicine and cellular longevity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Preclinical evidence and mechanistic insights of ligustilide in ischemic stroke: a systematic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Natural herbal extract roles and mechanisms in treating cerebral ischemia: A systematic review.Frontiers in pharmacology · 2024Pooled it
- Resistance to doxorubicin therapy in breast cancer cells could be attenuated by ligustilide: impact on autophagy and LncRNA H19.BMC complementary medicine and therapies · 2026Article
- The latest research progress of ligustilide in the prevention and treatment of central nervous system disorders.Frontiers in pharmacology · 2026Review
- Article
- In Vivo Insights into the Role of Astragaloside IV in Preventing and Treating Civilization Diseases: A Comprehensive Review.International journal of molecular sciences · 2025Review
- Traditional Chinese medicines alleviate experimental chronic cerebral hypoperfusion injury through multi-components and multi-target mechanisms.Frontiers in pharmacology · 2025Review
- Neuroimaging and molecular mechanism of action of Cang-ai volatile oil in the treatment of vascular cognitive impairment.Frontiers in neuroscience · 2025Article
- Z-Ligustilide: A Potential Therapeutic Agent for Atherosclerosis Complicating Cerebrovascular Disease.Biomolecules · 2024Review
- Brozopine ameliorates cognitive impairment via upregulating Nrf2, antioxidation and anti-inflammation activities.Frontiers in pharmacology · 2024Article
- Article
- Natural essential oils derived from herbal medicines: A promising therapy strategy for treating cognitive impairment.Frontiers in aging neuroscience · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular dementia (VaD), the second cause of dementia, is caused by chronic cerebral hypoperfusion, producing progressive damage to cerebral cortex, hippocampus, and white matter. Ligustilide (LIG), one of the main active ingredients of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.